Gilead’s 4th-qtr sales and earnings beat expectations, as Harvoni soars

Gilead’s 4th-qtr sales and earnings beat expectations, as Harvoni soars

03-02-2016 Comments (0)Print

More on this story

Other stories of interest

In context

Related news from the web

Related People

Related Companies

US biotech giant Gilead Sciences saw its shares rise 2.2% to $84.48 in after-hours trading yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

More on this story

Other stories of interest

In context

Related news from the web

Related People

Related Companies

Take a Free Trial

What you get

Access The Pharma Letter's latest news free for 7 days

alt

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year
Only £77 per month or £820 per year

alt

  • No-limits access to our the site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

Click here to subscribe

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. Its part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Back to top